



11<sup>th</sup> February, 2021

<b>To,</b> <b>Department of Corporate Services</b> <b>BSE Ltd.</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.	<b>To,</b> <b>The Manager,</b> <b>Listing Department,</b> <b>National Stock Exchange of India Ltd.</b> “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.
<b>Ref.: Scrip Code No. : 540701</b>	<b>Ref. : (i) Symbol – DCAL</b> <b>(ii) Series – EQ</b>

**SUB.: DISCLOSURE PURSUANT TO REGULATION 30 OF SEBI (LODR) REGULATIONS, 2015 – BUSINESS UPDATES**

Dear Sir,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, we hereby inform about the business updates as under:

➤ **EDQM Update at Bavla Site:**

As informed earlier, there was a joint inspection carried out during the quarter ending March, 2020 by the Swissmedic and European Directorate for the Quality of Medicines & HealthCare (EDQM), due to which there were certain audit observations issued deficient to EU GMP Part II and other relevant Annexes for the company's Bavla site. The company performed risk analysis on products other than the ones related to suspended Certificates of Suitability (CEPs) as well during the quarter, according to the customer requirements. The company has already started manufacturing certain products from the Bavla site and successfully passed audits by two large clients. The implementation of the Corrective Action Plan submitted to the EDQM is already underway and on track wherein the company should be able to successfully address the audit observations.

➤ **CRAMS New molecules**

1. We have successfully completed validation at our site of the drug linker in December for one Oncology ADC, which is for multiple indications. The client performs the conjugation to the antibody at their own facilities. Next campaign is already planned, which would be the first commercial campaign from our facilities.



**Dishman Carbogen Amcis Limited**

Regd. Off.: DISHMAN CORPORATE HOUSE  
Iscon-Bopal Road, Ambli, Ahmedabad-380 058, Gujarat, India.  
Phone : +91 (0) 2717 420102 / 2717 420124

E-mail : [dcald@dishmangroup.com](mailto:dcald@dishmangroup.com)  
Website : [www.dishmangroup.com](http://www.dishmangroup.com)

Government Recognised Export House  
CIN No. : L74900GJ2007PLC051338



2. We completed validation for a molecule in Hypoparathyroidism in December 2020, for the linker and 3 building blocks. We shall be now engaging into detailed discussions on supply agreement and detailed forecast.
3. Our first full ADC has had its Investigational New Drug (IND) application approved by the USFDA and it shall progress to Phase I/II trials immediately.
4. Three programmes have recently entered late Phase III. One is for a large US based pharma company where we have been developing ADC Drug linker for a few years. Another one is for a US based biotech company in oncology and the third one is also for a US based biotech company focussed on Hypoxia. The last one may see accelerated review as it possibly has an impact on COVID.
5. A commercial product made for a large USA pharma client has been increased in batch size during QIII FY 2021. This product is a broad range antibiotic, and we believe the increase in volumes is related to its use in pneumonia patients possibly linked to COVID.
6. We manufacture a GMP precursor for a commercial oncology product once every 2 years, this campaign commences in May 2021, which would be a good revenue contributor for next year.
7. In Europe average requests for proposals in 20/21 are up 10% on last FY19/20. Development Pipeline sits at CHF 94m as of December 2020, this is the highest in last 4 years.

➤ **Vitamin D**

1. Our development teams are working on 3 new projects in the synthetic cholesterol, and Vitamin D2 areas that we are prioritising across both India and Holland R&D teams.
2. We are in late stage of patent filing as mentioned previously. We have had confirmation in early January that The European Patent office has formally recognised the novelty of our claims for our product i.e., supplement for obesity patients and other mal absorbers of vitamin D as a result of our study work in the USA.
3. For the COVID clinical trial in Middle East, we have now received a batch of preliminary data and we expect the full detailed package of data will be received in next quarter. The next step will be a medical peer publication of our findings.



**Dishman Carbogen Amcis Limited**

Regd. Off.: DISHMAN CORPORATE HOUSE  
Iscon-Bopal Road, Ambli, Ahmedabad-380 058, Gujarat, India.  
Phone : +91 (0) 2717 420102 / 2717 420124

E-mail : [dcal@dishmangroup.com](mailto:dcal@dishmangroup.com)  
Website : [www.dishmangroup.com](http://www.dishmangroup.com)

Government Recognised Export House  
CIN No. : L74900GJ2007PLC051338



➤ **Disinfectants**

Between February 2020 and December 2020, we supplied 300 metric tonnes of concentrated disinfectant and anti-bacterial products to our clients around the globe to assist in the fight against COVID.

Kindly take this on your record.

Yours faithfully,

**For, Dishman Carbogen Amcis Limited**

*Sr. Dave*  
**Shrima Dave**  
**Company Secretary**



**Dishman Carbogen Amcis Limited**

Regd. Off.: DISHMAN CORPORATE HOUSE  
Iscon-Bopal Road, Ambli, Ahmedabad-380 058, Gujarat, India.  
Phone : +91 (0) 2717 420102 / 2717 420124

E-mail : [dcal@dishmangroup.com](mailto:dcal@dishmangroup.com)  
Website : [www.dishmangroup.com](http://www.dishmangroup.com)

Government Recognised Export House  
CIN No. : L74900GJ2007PLC051338